Peter Pechan Email & Phone Number | Over 20 years of biotechnology industry experience in gene therapy field. Previously at LogicBio, SolidBio, Voyager, Biogen and Genzyme worked to establish AAV gene therapy vectors technology and supporting gene therapy programs. At at Genzyme-Sanofi developed experimental drug candidates for ocular gene therapy programs, including one program by generating an experimental drug candidate sFLT01 that was tested in phase 1b of clinical trial (wet AMD gene therapy) and was also leading a project to treat myocilin-type glaucoma(POAG) by gene therapy. Has previous experience in early gene therapy companies, Canji Inc.(Schering-Plough) and Genetic Therapy Inc. (Novartis). Received Ph.D, in Molecular Biology and Neurobiology from University of Tübingen, Germany and MSc. in Biotechnology from Slovak Technical University , Bratislava, Slovakia. Completed a post-doctoral fellowship (Harvard Medical School Neuroscience Program) at Massachusetts General Hospital in Charlestown, MA.

Peter Pechan

Over 20 years of biotechnology industry experience in gene therapy field. Previously at LogicBio, S...
United States

*50 free lookup(s) per month.

No credit card required.

Peter Pechan’s Email peter.pechan@ucb.com

Peter Pechan’s Phone Numbers

Get PETER’s Phone Number (For Free)

Social Media

Peter Pechan’s Location United States

Peter Pechan’s Current Industry Ucb

Not the Peter Pechan you were looking for?

Find accurate emails & phone numbers for over 700M professionals.

Work Experience

Ucb

Head of Vector Biology, GTVC

2022-02-01 00:00:00 - Present

Logicbio Therapeutics

Vice President, Gene Therapy

2021-03-01 00:00:00 - 2021-12-01 00:00:00

Solid Biosciences

Senior Director, Vector Biology

2018-04-01 00:00:00 - 2021-03-01 00:00:00

Voyager Therapeutics

Director, AAV Vectors

2016-10-01 00:00:00 - 2018-04-01 00:00:00

Biogen

Principal Investigator, Gene Therapy, Head of Gene Transfer Technology

2015-08-01 00:00:00 - 2016-10-01 00:00:00

Sanofi Genzyme R And D Center

Principal Scientist, Gene Therapy

2000-01-01 00:00:00 - 2015-01-01 00:00:00

Canji Inc Schering Plough Research Institute

Senior Scientist

1998-01-01 00:00:00 - 2000-01-01 00:00:00

Genetic Therapy Inc Novartis

Senior Scientist

1997-01-01 00:00:00 - 1998-01-01 00:00:00

Harvard Medical School

Postdoctoral Research Fellow Neuroscience Program

1993-01-01 00:00:00 - 1997-01-01 00:00:00

Skills

No Skills Available

Languages

No Languages Available

FAQ About Peter Pechan

Peter Pechan is located at
United States

Peter Pechan is a Over 20 years of biotechnology industry experience in gene therapy field. Previously at LogicBio, SolidBio, Voyager, Biogen and Genzyme worked to establish AAV gene therapy vectors technology and supporting gene therapy programs. At at Genzyme-Sanofi developed experimental drug candidates for ocular gene therapy programs, including one program by generating an experimental drug candidate sFLT01 that was tested in phase 1b of clinical trial (wet AMD gene therapy) and was also leading a project to treat myocilin-type glaucoma(POAG) by gene therapy. Has previous experience in early gene therapy companies, Canji Inc.(Schering-Plough) and Genetic Therapy Inc. (Novartis). Received Ph.D, in Molecular Biology and Neurobiology from University of Tübingen, Germany and MSc. in Biotechnology from Slovak Technical University , Bratislava, Slovakia. Completed a post-doctoral fellowship (Harvard Medical School Neuroscience Program) at Massachusetts General Hospital in Charlestown, MA.

Peter Pechan currently works in the Ucb |

No Languages Available

Peter Pechan has prior
experience in the following industries:
Logicbio Therapeutics | Solid Biosciences | Voyager Therapeutics | Biogen | Sanofi Genzyme R And D Center | Canji Inc Schering Plough Research Institute | Genetic Therapy Inc Novartis | Harvard Medical School

Peter Pechan has the following professional experience:
Ucb | Logicbio Therapeutics | Solid Biosciences | Voyager Therapeutics | Biogen | Sanofi Genzyme R And D Center | Canji Inc Schering Plough Research Institute | Genetic Therapy Inc Novartis | Harvard Medical School